[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100532069":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":7,"locations":8,"responsibleParty":28,"collaborators":7,"id":32,"slug":7,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":35,"acronym":36,"eligibilityCriteria":37,"healthyVolunteers":38,"sex":39,"minAge":40,"maxAge":7,"enrollmentInfo":41,"targetDuration":7,"studyType":44,"phases":7,"briefSummary":45,"conditions":46,"keywords":7,"overallStatus":11,"whyStopped":7,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":58},{"fullName":5,"class":6},"University Medical Center Goettingen","OTHER",null,[9],{"facility":10,"status":11,"city":12,"state":13,"zip":14,"country":15,"cosmosGeoPoint":16,"geoPoint":21,"contacts":22},"Universitätsmedizin Göttingen","RECRUITING","Göttingen","Lower Saxony","37075","Germany",{"type":17,"coordinates":18},"Point",[19,20],9.93228,51.53443,{"lat":20,"lon":19},[23],{"name":24,"role":25,"phone":26,"phoneExt":7,"email":27},"Alexander Schulz, Dr. med.","CONTACT","0049 551 3967601","alexander.schulz@med.uni-goettingen.de",{"type":29,"investigatorFullName":30,"investigatorTitle":31,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Alexander Schulz","Principal Investigator","100532069",false,"NCT06208007","Arterial Stiffening as a Predictor for Diastolic Cardiac Dysfunction and HFpEF","ARTSPREDICTION","Inclusion Criteria:\n\nOne or more of the following criteria:\n\n* Age \\> 60 years\n* Arterial hypertension (RR systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg or ≥ 2 antihypertensive drugs)\n* Diabetes mellitus Type I or II\n* Atrial fibrillation\n* Chronic kidney disease (GFR \\\u003C 60 ml\u002Fmin\u002F1,73 m2 or urine albumin ≥ 30mg\u002F24h or ACR ≥ 30 mg\u002Fg)\n* BMI ≥ 30 kg\u002Fm2\n* NYHA ≥ II\n* E\u002Fe' \\> 8\n\nExclusion Criteria:\n\n* Left ventricular ejection fraction \\\u003C 50 %\n* Significant valve disease (Grade III or higher)\n* History of interventional or surgical valve repair\n* Regional wall motion abnormalities\n* Respiratory diseases as a known cause for dyspnea\n* Atrial flutter or fibrillation during examination\n* Hypertrophic\u002Frestrictive\u002Farrhythmogenic\u002Fdilatative cardiomyopathies including cardiac amyloidosis or sarcoidosis and toxic cardiomyopathy\n* History of heart transplantation",true,"ALL","18 Years",{"count":42,"type":43},150,"ESTIMATED","OBSERVATIONAL","Patients at risk for developing heart failure with preserved ejection fraction (HFpEF) will undergo a structured clinical assessment, transthoracic echocardiography and pulse-wave analysis to investigate the association of arterial stiffening and the development of cardiac diastolic dysfuntion and HFpEF.",[47,48],"Heart Failure With Preserved Ejection Fraction","Cardiovascular Morbidity","2024-05-08",{"date":51,"type":52},"2024-05-09","ACTUAL",{"date":54,"type":52},"2024-02-23",{"date":56,"type":43},"2028-01",{"name":5,"class":6},1]